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Background
Chronic isolated inflammatory coxitis (CIIC) is character-
ized by exclusive involvement of coxo-femoral joints and
an aggressive course leading to permanent structural dam-
age, often requiring surgical treatment. Early commence-
ment of disease-modifying or corticosteroid therapy has
been suggested. To date, treatment with biological agents
has not been reported. We describe the favourable
response to etanercept in two girls with CIIC.
Patients
Patient 1 (15 years) and patient 2 (17 years) presented
with a history of hip pain and limp lasting 3 and 5 years,
respectively. Previous disease-modifying therapy was
uneffective. Hip radiograph showed bilateral joint space
narrowing in both patients and ankylosis of right hip in
patient 2. ANA and HLA-B27 were negative in both cases.
Active phase reactants were mildly increased in patient 2.
Magnetic resonance imaging (MRI) was obtained imme-
diately before and after treatment with etanercept.
Results
Treatment with etanercept was followed by a significant
improvement of pain and limitation of motion in patient
1: MRI after 6 months showed considerable reduction of
synovial effusion. Synovitis and bone marrow oedema of
femoral head, previously visualized, were not detectable.
Mild clinical improvement and normalization of inflam-
matory parameters were observed in patient 2: MRI after
12 months showed no progression of structural damage.
MRI findings of disease activity were not detectable.
Conclusion
Etanercept treatment was effective in our patients. Clinical
and radiological improvement was more evident in the
patient with a shorter disease duration. Early treatment
with anti-TNF agents should be considered in patients
with CIIC to prevent severe structural damage.
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